BeiGene Clinches Asian Rights to Four RAS(ON) Inhibitors in Revolution Medicines Deal

On August 10, 2026, BeiGene announced a clinical collaboration agreement with Revolution Medicines to evaluate combination regimens of selected BeiGene oncology candidates in clinical development with four RAS(ON) inhibitors from Revolution Medicines. Under a separate regional licensing agreement, BeiGene will obtain exclusive development and commercialization rights to these candidates in select Asian markets. Revolution Medicines is eligible to receive development and sales milestone payments, as well as tiered royalties on net sales in the licensed territory, while retaining development and commercialization rights outside the licensed region, including Japan and South Korea.

The four RAS(ON) inhibitors are daraxonrasib, zoldonrasib, elironrasib, and RMC-5127. Planned combination studies include BeiGene's MTA-cooperative PRMT5 inhibitor BGB-58067 and its EGFR×MET×MET trispecific antibody BG-T187, each paired with daraxonrasib or zoldonrasib. These agents target the range of RAS mutations prevalent in pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). Clinical data presented at the American Society of Clinical Oncology annual meeting in May 2026 showed that daraxonrasib extended median overall survival to 13.2 months in patients with advanced pancreatic cancer, versus 6.7 months for the chemotherapy group, a 60% reduction in the risk of death.

Zoldonrasib is the most advanced RAS(ON) G12D-selective inhibitor in global development. Data first disclosed in the second-quarter 2026 earnings report showed that zoldonrasib and elironrasib, each combined with pembrolizumab plus platinum-based doublet chemotherapy for NSCLC, achieved objective response rates exceeding 80%.

As part of the transaction, BeiGene will fund and conduct a global registrational Phase 3 study of Revolution Medicines' RAS(ON) inhibitors, while Revolution Medicines will continue to advance other global registrational studies in its portfolio. The U. S. Food and Drug Administration has approved two KRAS inhibitors for KRAS G12C-mutant NSCLC, but no targeted therapy yet exists for KRAS G12D mutations, which occur in approximately 4% of NSCLC patients and are also found in pancreatic and other gastrointestinal cancers. The collaboration aims to advance combination regimens through a two-way binding of research and development and commercialization.